



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

09 Mar 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard ([eugeneb@sun.ac.za](mailto:eugeneb@sun.ac.za)), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

### Important notices

- Eye on NIH Policy: OMB Uniform Guidance - What it Means for NIH & You (Video & Interactive Q&A - March 12, 2015) ([NOT-OD-15-077](#))
- NCCIH Policy for Submission of R21 Applications Containing Clinical Trials ([NOT-AT-15-004](#))
- [Saving Lives at Birth: A Grand Challenge for Development](#) aims to find the tools and approaches to help the mothers and newborns in poor, hard-to-reach communities around the time of delivery and during their most vulnerable hours. The Broad Agency Announcement (BAA) is supported by USAID, the Government of Norway, the Bill and Melinda Gates Foundation, Grand Challenges Canada, and DFID. Application Platform has opened February 16.

### 1. Title: Biological and Physiological Effects of E-cigarette Aerosol Mixtures

Letter of Intent due date: June 28, 2015 Hyperlink: [\(RFA-DE-16-004\)](#) Type: RO1  
[\(RFA-DE-16-005\)](#) R21

Application Due Date: July 28, 2015, by 5:00 PM local time of applicant organization.

**Purpose:** The purpose of this FOA is to support research aimed at understanding the biological and physiological effects of aerosol mixtures produced by electronic cigarettes (ECs) on cells, tissues and organs of the oral cavity including oral and periodontal epithelia, gingiva, salivary glands, and tooth. This FOA will also support research on elucidation of the effects of ECs on oral microbiome. Research supported by this FOA would provide essential and necessary information on the biological effects of ECs that would in turn lead to evidence based foundational information for health policy decisions

**Budget:** RO1: Application budgets are limited to \$250,000 per year in direct costs and need to reflect the actual needs of the proposed project. Max period 4 years. R21: Application budgets are limited to \$150,000 per year in direct costs and need to reflect the actual needs of the proposed project. Max period 2 years.

### 2. Title: Functional Wellness in HIV: Maximizing the Treatment Cascade

Letter of Intent due date: N/A Hyperlink: [\(PA-15-133\)](#) Type: RO1  
[\(PA-15-134\)](#) R21

Application Due Date: May 7, 2015 Sep 7, 2015 and Jan 7, 2016 by 5:00 PM local time of applicant organization.

**Purpose:** This FOA seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.

**Budget:** RO1: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years. R21: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year.

### 3. Title: Investigations on Primary Immunodeficiency Diseases

Letter of Intent due date: N/A Hyperlink: [\(PAR-15-130\)](#) Type: RO1

Application Due Date: June 5, 2015; Oct 5, 2015; Feb 5, 2016 by 5:00 PM local time of applicant organization

**Purpose:** This Funding Opportunity Announcement (FOA) is intended to support innovative investigations in primary immunodeficiency diseases. Of particular interest are the detection of primary immunodeficiency diseases, the identification of the molecular basis of these diseases, and the design and pre-clinical development of innovative therapies for these diseases.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Max period is 5 years

### 4. Title: Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions

Letter of Intent due date: 30 days prior to the application due date Hyperlink: [\(PAR-15-131\)](#) Type: G11

Application Due Date: July 15, 2015; July 15, 2016; July 15, 2017 by 5:00 PM local time of applicant organization.

**Purpose:** Only one application per institution is allowed. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.

**Budget:** Application budgets are limited to \$100,000 in direct costs for the total period of 18 months.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**UH2/UH3 - Phase Innovation Awards Cooperative Agreement:** Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)



**Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa de Vries** • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)